Weekly Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings

May 17, 2018 - By Robert Reynolds

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
During Q4 2017 the big money sentiment increased to 3. That’s change of 2.21, from 2017Q3’s 0.79. 6 investors sold all, 5 reduced holdings as Dicerna Pharmaceuticals, Inc. ratio is positive. 15 rose positions while 18 funds took positions. Funds hold 29.10 million shares thus 180.62% more from 2017Q3’s 10.37 million shares.
Emerald Mutual Fund Advisers holds 0.2% or 570,861 shs. Ecor1 Cap Ltd Limited Liability Company invested in 4.92% or 4.84M shs. Eam Investors Limited Company holds 64,340 shs. Bancorp Of New York Mellon stated it has 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Moreover, Endurant Cap Management Ltd Partnership has 0.05% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 683 Cap Management Lc has invested 0.42% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Geode Management Limited Liability Corp, a Massachusetts-based fund reported 91,737 shs. 10,560 were reported by Tower Rech Cap Ltd Liability Corp (Trc). Royal Commercial Bank Of Canada accumulated 1,016 shs. Vanguard Group Inc Inc stated it has 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bank Of America Corp De stated it has 35 shs. Dimensional Fund Advsr Lp accumulated 18,244 shs. California Public Employees Retirement Systems invested 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Deutsche National Bank Ag stated it has 168,400 shs. Morgan Stanley has 1,874 shs.

Dicerna Pharmaceuticals, Inc. had 4 selling transactions and 1 buy since December 18, 2017. This’s net activity of $1.57 million. On Wednesday, May 9 a trade for 9,669 shs valued at $145,035 was made by Brown Bob D. 10,000 Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shs with value of $150,000 were sold by Weissman James B.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

A total of 8 analysts rate Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:DRNA) has 8 ratings reports on May 17, 2018 according to StockzIntelligence. On Friday, March 23 the rating was downgraded by H.C. Wainwright to “Neutral”. On Tuesday, March 27 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Hold” rating given by FBR Capital. On Wednesday, April 11 Cowen & Co initiated Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) with “Buy” rating. In Monday, February 5 report SunTrust initiated the stock with “Buy” rating. The stock rating was maintained by Stifel Nicolaus with “Buy” on Friday, March 9. In Friday, March 9 report Chardan Capital Markets initiated the stock with “Hold” rating. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

DRNA is hitting $13.76 during the last trading session, after decreased 0.04%.Dicerna Pharmaceuticals, Inc. has volume of 29,107 shares. Since May 17, 2017 DRNA has risen 274.53% and is uptrending. DRNA outperformed the S&P500 by 262.98%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is valued at $712.73 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by Streetinsider.com, Benzinga.com and Businesswire.com. The first one has “Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel” as a title and was published on May 15, 2018. The next is “Earnings Scheduled For May 14, 2018” on May 14, 2018. And last was published on May 14, 2018, called “Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update”.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.